PVDF-HFP-based polymer inclusion membrane functionalized with D2EHPA for the selective extraction of bismuth(III) from sulfate media.

This study is the first application of a PVDF-HFP-based polymer inclusion membrane incorporating the poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP) and di(2-ethylhexyl)phosphoric acid (D2EHPA) as the base polymer and extractant for the extraction of bismuth(III), respectively. It is demonstrated that the PIM comprised of 60 wt% PVDF-HFP and 40 wt% D2EHPA is the most effective in the extraction of bismuth(III) from feed solution containing 20 mg L-1 bismuth(III) and 0.2 mol L-1 sulfate adjusted to pH 1.4. The extracted bismuth(III) ions are back-extracted quantitatively to the receiving solution containing 1 mol L-1 sulfuric acid. The stoichiometry experiments reveal that the Bi: D2EHPA ratio in the bismuth(III) extracted complex is 1:6, and D2EHPA is dimer. Moreover, it is shown that the studied PIM has high selectivity in the extraction of bismuth(III) over other interfering ions such as Mo(VI), Cr(III), Al(III), Fe(III), Ni(II), Zn(II), Cd(II), Co(II), Cu(II), and Mn(II). The interference of Fe(III) is also eliminated by masking with fluoride, leading finally to a nearly pure extraction of bismuth(III).

Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.

AIMS: COVID-19 is a significant global threat to public health. Despite the availability of vaccines and anti-viral drugs, there is an urgent need for alternative treatments to help prevent and/or manage COVID-19 symptoms and the underlying dysregulated immune response. We hypothesized that administration of Inflawell® syrup, a Boswellia extract formulation enriched for boswellic acids (BAs), can reduce the excessive or persistent inflammation and thereby prevent disease progression. BAs are medicinally activated triterpenoids found in the resins of Boswellia spp., and possess an immense therapeutic potential due to their anti-inflammatory and immunoregulatory activities. We investigated the effect of Inflawell® syrup, on moderate COVID-19 patients along with the current standard of care treatment. METHODS: A randomized placebo-controlled double-blind clinical trial was conducted, following definitive confirmation of COVID-19. Forty-seven hospitalized patients with moderate COVID-19 were enrolled and received either the Inflawell® syrup or placebo. Clinical symptoms and markers of inflammation were evaluated at baseline and completion of the trial. RESULTS: Our clinical trial revealed an increase in the percentage of oxygen saturation level in patients that received the BAs compared to placebo (P < 0.0001). In addition, the average duration of hospitalization was significantly shorter in the BAs group compared with the placebo group (P < 0.04). Concomitantly, some improvement in the clinical symptoms including cough, dyspnea, myalgia, headache, and olfactory and gustatory dysfunction were detected in the BAs group. Hematologic findings showed a significant decrease in the percentage of neutrophils (P < 0.006) and neutrophil-to-lymphocyte ratio (NLR) levels (P < 0.003), associated with a significant increase in the percentage of lymphocytes in the BAs group compared with the placebo (P < 0.002). Additionally, a significant decrease in CRP, LDH, IL - 6 and TNF - α levels was detected in the BAs group. Following the intervention, fewer patients in the BAs group were PCR-positive for COVID-19 compared to placebo, though not statistically significant. CONCLUSION: Overall, the treatment with Inflawell® resulted in shorter hospital stay, alleviation of COVID-19 clinical symptoms and decline in the level of pro-inflammatory cytokines. TRIAL REGISTRATION: The trial has been registered in  https://www.irct.ir  with unique identifier: IRCT20170315033086N10 ( https://en.irct.ir/trial/51631 ). IRCT is a primary registry in the WHO registry network ( https://www.who.int/clinical-trials-registry-platform/network/primary-registries ).

Investigation of the Hg(II) biosorption from wastewater by using garlic plant and differential pulse voltammetry.

In this work, the bio sorption of mercury ion by garlic bio-adsorbent was studied. A batch and a continuous up-flow fixed-bed column system were used in this report. Differential pulse voltammetry was used to detecting the amount of mercury ion. Using Differential pulse voltammetry prevents the production of carcinogenic mercury vapor. In the batch system, various doses of bio-adsorbent were investigated. After that, the experimental data was fitted using Langmuir and Freundlich models. The experimental data were also fitted to the Thomas, Bohart-Adams, and Yan models for the continuous mode in a fixed bed of garlic bio-adsorbent. The maximum adsorption capacity estimated by the Thomas models was 23.5 mg g-1 and τ was 135.3 min. This adsorbent is also suitable for absorbing mercury from a real-life well water sample. It is renewable and can be used to absorb mercury several times.

The multiplicative interactions of leukocyte counts with some other risk factors enhance the prognostic value for coronary artery disease.

BACKGROUND: The markers of inflammation and (apo)lipoproteins are associated with coronary artery disease (CAD). Simultaneous assessment of the risk factors has been proposed to improve the diagnosis of CAD. The aim of this study was to examine the potential interactions between leukocyte counts and other risk factors. METHODS: The markers of inflammation, (apo)(lipo)proteins, (non)electrolytes, hematological parameters and classical risk factors, were determined in 264 clinically stable angiographically documented subjects. The subjects were classified as CAD cases or controls according to the results of coronary angiography. RESULTS: The frequency and severity of CAD, Framingham CAD scores, relative and absolute risk for CAD and the prevalence of diabetes mellitus and smoking were significantly higher in the third relative to the first tertile of leukocyte counts. Subjects with leukocyte counts in the upper tertile had significant higher levels of serum glucose, triglyceride, hsC-reactive protein, potassium, phosphorus and measured osmolality, and lower levels of apoAI, total protein, albumin and the ratio of albumin/globulins. Analyses by bivariate correlation on differential leukocyte counts showed that these associations are carried mostly by neutrophil, except for diabetes, glucose and triglyceride which were due to lymphocyte counts. By constructing dummy combined variables, high leukocyte counts accompanied by smoking, hypertension, diabetes, and high levels of serum glucose, cholesterol, apoB and apoB/apoAI ratio, exhibited amplified high risk for CAD. CONCLUSIONS: The results show that leukocyte count does interact multiplicatively with smoking, hypertension, diabetes, glucose, cholesterol, apoB and apoB/AI ratio. The simultaneous assessment of leukocyte counts and interactive risk factors enhances the diagnosis of CAD.